# US 2026/0256737 A1 · Compositions for pathogenesis-directed therapy and treatments of skin diseases and disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0256737 A1
- Document ID: US20260256737A1
- Status: Published application
- Kind: A1
- Application number: 19/659,139
- Filed: 2026-04-27
- Published: 2026-09-03
- Earliest claimed: 2019-06-11
- Assignees: Yale University
- Applicants: Yale University
- Inventors: Keith Choate; Lihi R. Atzmony
- Web page: https://patentgrep.com/patent/US20260256737A1

## CPC

- A61K 31/366: having six-membered rings, e.g. delta-lactones
- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 31/22: of acyclic acids, e.g. pravastatin
- A61K 31/40: having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K 31/404: Indoles, e.g. pindolol
- A61K 31/47: Quinolines; Isoquinolines
- A61K 31/505: Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K 31/575: substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/12: Keratolytics, e.g. wart or anti-corn preparations
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to compositions comprising at least one lipid-lowering drug or a derivative thereof for the treatment of skin diseases or disorders. In various aspects of the invention, the composition further comprises at least one lipid or a derivative thereof.

## Claims

### Claim at position 1

1-34. (canceled)

### Claim 35

A method of treating porokeratosis, the method comprising topically administering a therapeutically effective amount of a composition to a subject in need thereof,
wherein the composition comprises a 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase inhibitor,
wherein the porokeratosis is one selected from the group consisting of plaque-type porokeratosis (porokeratosis of Mibelli), disseminated superficial actinic porokeratosis (DSAP), disseminated superficial porokeratosis (DSP), porokeratosis palmaris et plantaris disseminate (PPPD), linear porokeratos (LP), punctate porokeratosis, porokeratosis plantaris discrete, porokeratosis ptychotropica, porokeratoma, solar facial porokeratosis, hyperkeratotic porokeratosis, and any combination thereof, and
wherein the porokeratosis in the subject is treated.

### Claim 36 (depends on 35)

The method of claim 35, wherein the HMG-CoA reductase inhibitor is present in an amount of about 0.1% to about 25%.

### Claim 37 (depends on 35)

The method of claim 35, wherein the HMG-CoA reductase inhibitor is present in an amount of about 1% to about 10%.

### Claim 38 (depends on 35)

The method of claim 35, wherein the HMG-CoA reductase inhibitor is present in an amount of about 2%.

### Claim 39 (depends on 35)

The method of claim 35, wherein the HMG-CoA reductase inhibitor is selected from the group consisting of atorvastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin, simvastatin, pitavastatin, and any combination thereof.

### Claim 40 (depends on 35)

The method of claim 35, wherein the composition is topically administered at least one time per day.

### Claim 41 (depends on 35)

The method of claim 35, wherein the composition is administered at least one time per day for a duration of 6 months.

### Claim 42 (depends on 35)

The method of claim 35, wherein the composition is administered at least one time per day for a duration of 4 to 6 weeks.

### Claim 43 (depends on 35)

The method of claim 35, wherein the composition is administered at least two times per day for a duration of 4 to 6 weeks.

### Claim 44 (depends on 35)

The method of claim 35, wherein the composition further comprises one or more pharmaceutically acceptable carriers or excipients.

### Claim 45 (depends on 35)

The method of claim 35, wherein the composition further comprises at least one lipid.

### Claim 46 (depends on 45)

The method of claim 45, wherein the at least one lipid is a cholesterol.

### Claim 47 (depends on 45)

The method of claim 45, wherein the at least one lipid or derivative thereof is present in an amount of about 0.1% to about 25%.

### Claim 48 (depends on 45)

The method of claim 45, wherein the at least one lipid or derivative thereof is present in an amount of about 1% to about 10%.

### Claim 49 (depends on 45)

The method of claim 45, wherein the at least one lipid or derivative thereof is present in an amount of about 2%.

### Claim 50 (depends on 35)

The method of claim 35, wherein treating the porokeratosis in the subject results in one or more effects selected from the group consisting of a decrease in scaling, a decrease in erythema, a decrease in inflammation, a decrease in number of lesions, a decrease in size of lesions, a decrease in thickness of lesions, and any combination thereof.
